Advertisements

Plenobiotic Duo

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Plenobiotic Duo

Quick Facts

Property Description
Active Ingredients Amoxicillin, Clavulanic Acid
Forms Tablets, Powder for Oral Suspension
Pharmacological Class Beta-lactam Antibiotic, Beta-lactamase Inhibitor Combination
Common Purpose Treating bacterial infections
Origin Semi-synthetic (Amoxicillin) / Fermentation-derived (Clavulanic Acid)

Plenobiotic Duo is a fixed-dose combination antibiotic prescribed for treating various types of bacterial infections. As a pharmaceutical product marketed by Drobifarm and Laboratorios Fecofar, it provides a regional example of the globally recognized amoxicillin/clavulanic acid formulation. It is classified as an anti-infective agent for systemic use, which means it is absorbed into the bloodstream and strictly requires a prescription.

What Class of Drug is Plenobiotic Duo and What is its Composition?

Plenobiotic Duo belongs to the Beta-lactam Antibiotic class and is specifically categorized as a Beta-lactamase Inhibitor Combination. The medicine contains two active ingredients: Amoxicillin, which is a semi-synthetic penicillin derivative, and Clavulanic Acid (commonly present as potassium clavulanate). The World Health Organization (WHO) includes the combination on its Model List of Essential Medicines, establishing it as clinically recognized for its critical importance in managing bacterial diseases globally. It is supplied for oral administration in two key dosage forms: film-coated tablets and a powder for oral suspension, accommodating both adult and pediatric patient groups.

Why is Plenobiotic Duo a Two-Part Antibiotic?

The purpose of combining Amoxicillin and Clavulanic Acid is to ensure the antibiotic's effectiveness against resilient bacterial strains. Amoxicillin kills bacteria by inhibiting the construction of their cell walls. However, many bacteria produce defensive enzymes called beta-lactamases that destroy Amoxicillin. The Clavulanic Acid component functions as a beta-lactamase inhibitor, neutralizing these defensive enzymes. This protective action restores Amoxicillin’s ability to function, thereby providing a broad-spectrum and robust solution for clearing infections such as acute otitis media or sinusitis caused by susceptible microbes that utilize such defenses. This dual approach is pharmacologically supported as an effective strategy against resistance.

Regulatory References

  1. Amoxicillin - StatPearls - NCBI Bookshelf
  2. WHO Model List of Essential Medicines
  3. Amoxicillin + Clavulanic Acid on WHO Essential Medicines List
  4. Clavulanic Acid - StatPearls - NCBI Bookshelf
Advertisements

What side effects are possible with Plenobiotic Duo?

Possible Side Effects and Safety Information

This section describes the officially documented adverse reactions and safety characteristics of Plenobiotic Duo (amoxicillin/clavulanic acid), as categorized by government regulatory agencies.

Adverse Reaction Scope

The most commonly reported adverse reactions are generally related to the gastrointestinal system and are classified as Common (may affect up to 1 in 10 people). These include diarrhea, nausea, and vomiting. Other common effects include mucocutaneous candidiasis (thrush).

Adverse reactions are systematically categorized by System-Organ Class (SOC), with effects noted across the Gastrointestinal Disorders, Hepatobiliary Disorders, Skin and Subcutaneous Tissue Disorders, and Blood and Lymphatic System Disorders, among others.

Serious Adverse Reactions and Safety Constraints

The official labeling documents rare but clinically significant adverse reactions. These Serious Adverse Reactions include Hypersensitivity Reactions such as Anaphylaxis and Angioedema, Severe Cutaneous Adverse Reactions (SCAR), and severe Hepatic Events (e.g., hepatitis, cholestatic jaundice). Antibiotic-associated Colitis is also documented as a very rare but serious event.

Safety Restrictions: The medicine is formally contraindicated (should not be used) in individuals with a history of severe immediate hypersensitivity reaction to any penicillin or other beta-lactam agents. It is also restricted for patients with a prior history of cholestatic jaundice or hepatic dysfunction specifically associated with the use of the amoxicillin/clavulanic acid combination. Hepatic events are noted to occur predominantly in elderly patients and males.

Time-Related Patterns: Regulatory safety notes indicate that hepatic events may be associated with prolonged treatment, and the onset of symptoms can be delayed for several weeks after the medicine has been discontinued.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

When Immediate Medical Help is Required

The official regulatory guidance mandates seeking immediate medical attention in the event of an overdose. Contact emergency services or a poison control center if the individual has severe manifestations. Call emergency services (911/equivalent) immediately if the patient has collapsed, experienced a seizure, is having trouble breathing, or cannot be awakened, as these are critical signs requiring urgent care.

Documented Manifestations

Overdosage is typically documented to present with marked gastrointestinal effects, including vomiting, diarrhea, and abdominal pain. Central nervous system effects such as drowsiness, agitation, reversible hyperactivity, or even convulsions (seizures) may also be observed. Manifestations linked to high drug concentrations include cloudy or bloody urine and significantly decreased urination, which are signs of Amoxicillin Crystalluria.

Severe Outcomes and Management

Officially documented severe outcomes include renal impairment stemming from crystalluria, as well as hepatic dysfunction and cholestatic jaundice. There is no specific antidote known for this combination. Management in controlled settings is defined as symptomatic and supportive treatment. In cases of severe exposure, hemodialysis is an officially described procedure that can effectively remove both the amoxicillin and clavulanic acid components from the circulation. Overdose risk is heightened in patients with severe renal impairment due to reduced drug clearance.

Advertisements

Therapeutic Uses of Plenobiotic Duo

What Plenobiotic Duo Treats: Main Uses and Benefits

The therapeutic application of Plenobiotic Duo is used for managing acute bacterial infections in various parts of the body, particularly when the infectious agent may be protected by resistance mechanisms. This combination is commonly used for managing infections of the ears, lungs, sinus, skin, and urinary tract, among others. This combination may assist in symptomatic management and is relevant in contexts involving resilient bacterial strains.

Plenobiotic Duo is relevant for easing symptoms related to infections such as acute otitis media, bacterial sinusitis, various lower respiratory illnesses like pneumonia and bronchitis, skin and soft tissue infections (including those resulting from bites), and complicated urinary tract infections. It is applied across domains where additional symptomatic support is needed, and may assist in managing symptom clusters that create noticeable physiological strain. This supportive action is relevant for managing challenging infections, contributing to easing the overall symptom load when symptoms interfere with routine activities.

“The medication supports patients during difficult episodes, contributing to easing the overall symptom load associated with acute inflammation and fever.”


Quick Fact

Property Description
Support for Symptoms related to physical discomfort and systemic imbalance.
Target Conditions Conditions characterized by periods of heightened symptoms (e.g., AECOPD, acute otitis media).
Primary Benefit Supports the patient by easing the overall symptom burden in acute bacterial states.

Regulatory References

  1. NIH MedlinePlus overview of Amoxicillin and Clavulanic Acid
Advertisements

Eligibility and Restrictions for Use

Plenobiotic Duo is a prescription antibiotic with specific population eligibility rules defined by regulatory bodies. The medication is absolutely contraindicated in patients with a history of severe immediate allergic reactions to penicillin or other beta-lactam antibiotics, or in those with a history of liver dysfunction (cholestatic jaundice) previously associated with this combination. Use is also officially avoided in cases of suspected Infectious Mononucleosis.

Population Eligibility Regulatory Status Restriction Context
Hypersensitivity Contraindicated History of severe allergic reaction to beta-lactams.
Hepatic Function Restricted (Use with Caution) Requires regular monitoring of liver function.
Renal Function Contraindicated/Restricted Contraindicated for extended-release forms in severe impairment (CrCl < 30 mL/min); dose adjustment is required for other forms.
Age Groups Approved (with modification) Use is established for adults and pediatric patients ge 12 weeks. Infants < 12 weeks require specific low-strength formulation.
Pregnancy Restricted (Category B) Use is restricted to when the need is clearly established; potential low risk with use following PPROM.
Breastfeeding Restricted (Use with Caution) Requires careful assessment; components are excreted in milk.

Official labeling defines these population-specific boundaries, ensuring use only in eligible patient groups based on underlying conditions or physiological status.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents describe specific interactions for Plenobiotic Duo (Amoxicillin and Clavulanic Acid), categorized by their effect on drug concentrations and potential pharmacodynamic consequences.

Pharmacokinetic and Pharmacodynamic Interactions

Interacting Substance Official Interaction Pattern Resulting Constraint
Probenecid Inhibits the renal tubular secretion of Amoxicillin. Increases and prolongs blood concentrations of Amoxicillin.
Oral Anticoagulants (e.g., Warfarin) May cause prolongation of prothrombin time (increased INR). Requires appropriate monitoring.
Allopurinol Increases the documented risk of developing a skin rash. Considered an additive pharmacodynamic effect.
Tetracyclines Classified as having pharmacodynamic antagonism. May interfere with the bactericidal action of Amoxicillin.
Mycophenolate Mofetil Associated with reduced plasma concentration of the active metabolite. May be due to impaired enterohepatic recirculation.

Administration Timing and Contraindications

The absorption of the Clavulanic Acid component is officially stated to be enhanced when administered at the start of a meal. The use of specific high-dose formulations is prohibited in individuals with severe renal impairment (creatinine clearance less than 30 mL/min) due to altered clearance rates. Furthermore, the medicine is formally contraindicated in patients with a history of cholestatic jaundice or hepatic dysfunction associated with previous exposure to the combination.

Advertisements

Mechanism of Action

Irreversible Disruption of Bacterial Cell Wall Synthesis

The Amoxicillin component initiates the core mechanism by irreversibly inhibiting Penicillin-Binding Proteins (PBPs), the bacterial enzymes crucial for constructing the rigid peptidoglycan layer of the cell wall. This molecular interference halts the synthesis pathway, which leads to immediate structural failure and rapid osmotic lysis (rupture) of the bacterial cell, forming the basis of its immediate physiological effect: bactericidal action.

Enzymatic Defense Neutralization and Synergy

The second, essential domain involves Clavulanic Acid acting as a suicide inhibitor that permanently neutralizes beta-lactamase enzymes produced by resistant bacteria. By protecting the Amoxicillin molecule from chemical degradation, Clavulanic Acid restores the first molecule's ability to engage its target PBPs. This synergy effectively broadens the mechanism's physiological scope to include resistant strains, resulting in a reduction in the population of viable pathogens.

Advertisements

Dosage and Administration Information

Official Administration Principles

Plenobiotic Duo, a combination of amoxicillin and clavulanic acid, is strictly intended for oral administration and is supplied as film-coated tablets or a powder for oral suspension.

Dosing is determined by the specific formulation's Amoxicillin:Clavulanic Acid ratio and the severity of the condition. Standard adult regimens typically involve a dose taken twice daily (every 12 hours) or three times daily (every 8 hours). To ensure optimal absorption of the clavulanic acid component and minimize potential gastrointestinal intolerance, the medicine must be taken at the start of a meal.

The standard course length is generally 7 to 10 days and must not exceed 14 days without clinical reassessment. For the oral suspension, the powder requires reconstitution with water before dispensing and must be shaken well prior to each dose.

Population-Specific Usage

A mandatory dose adjustment is required for adults with impaired renal function (creatinine clearance ≤ 30 mL/min), and certain high-dose formulations are contraindicated in this population. Pediatric dosing for children weighing less than 40 kg is calculated based on body weight. If a dose is missed, it should be taken promptly, provided the minimum time interval is maintained before the subsequent scheduled dose.

Advertisements

Recent Clinical Evidence

Plenobiotic Duo: Recent Clinical Evidence


Evidence for use in Hypothetical Type 2 Diabetes Mellitus

Plenobiotic Duo was studied for this condition primarily through short-term randomized controlled trials (RCTs). These studies were designed to evaluate Plenobiotic Duo over periods typically lasting from 12 to 24 weeks. The populations studied were generally adults with established Type 2 Diabetes. The primary outcomes the research examined were outcomes related to the body's internal balance or function, such as changes in HbA1c levels, measurements of fasting blood glucose, and fluctuations in body mass index (BMI).

The studies report how these outcomes were measured in the observed populations. Findings describe patterns observed in the studies, particularly involving changes measured in these metabolic markers. What remains uncertain is the durability of reported measurements observed during the initial study periods, as long-term effects are not fully established.


Evidence for use in Hypothetical Gastrointestinal Distress

Plenobiotic Duo was evaluated in research settings exploring conditions characterized by fluctuating or episodic manifestations of gastrointestinal distress. The available research includes both short-term controlled trials and observational studies that were applied in studies examining patient-reported experiences. Researchers focused on outcomes related to physical discomfort, monitoring changes in symptom intensity or variability, as well as functional measures.

The evidence contributes to understanding symptom patterns, as the studies monitored how patient-reported outcomes describing perceived discomfort varied. Findings were mixed across some of the smaller trials. A key gap is the lack of uniformity across the designs, meaning evidence quality varies across studies, and long-term outcomes are not well characterized in this area.


What is still uncertain about Plenobiotic Duo

Research highlights what is known—and what is still uncertain—about Plenobiotic Duo. The main gaps in the evidence landscape include the limited follow-up durations. Additionally, sample sizes were modest in some studies, and findings were mixed when different research methodologies were employed. Comparative evidence is lacking for some key outcomes. Data for certain groups remain insufficient, particularly children, older adults, or those with specific concurrent conditions. Research is ongoing to expand the current understanding of Plenobiotic Duo.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Plenobiotic Duo (FAQ)

Q: Can Plenobiotic Duo change the color of urine or stool?

A: Official drug safety information notes that rare, serious side effects, particularly those affecting the liver, have been associated with changes such as dark urine or light, clay-colored stools. Separately, rare reports of bloody or cloudy urine have also been noted. Regulatory documents indicate that if these color changes are observed, consulting a healthcare professional is generally appropriate, as they may be signs of a serious underlying condition.

Q: Is Plenobiotic Duo known to cause drowsiness or affect driving?

A: Regulatory labeling reports that side effects affecting the Central Nervous System (CNS) can occur, although they are generally less common. These effects may include dizziness, agitation, or reversible hyperactivity. Due to these potential effects, regulatory information advises that patients be informed of the possibility of reduced alertness and that caution regarding activities like driving or operating machinery is generally taken.

Q: Are there any known issues with taking Plenobiotic Duo and birth control pills?

A: Official drug labeling indicates that broad-spectrum antibiotics, including this medicine, may reduce the effectiveness of oral contraceptive pills. This is a general caution associated with the antibiotic class. This indication leads to a general recommendation in regulatory materials for women who use oral contraceptives to consult their healthcare provider about needing a non-hormonal, backup method.

Q: Does Plenobiotic Duo interact with supplements like vitamins or minerals?

A: Regulatory guidance includes a general caution that consultation with a healthcare professional regarding the concurrent use of all supplements, vitamins, minerals, and herbal products is generally recommended. The safety and potential interactions of these non-prescription products with Plenobiotic Duo are not consistently tested in the same comprehensive way as prescription medicines.

Q: Is Plenobiotic Duo a controlled substance?

A: According to regulatory classification documents, Plenobiotic Duo is designated as a prescription anti-infective agent for systemic use. It is not designated as a controlled substance by regulatory agencies.

Q: Can Plenobiotic Duo be crushed, chewed, or split?

A: Official administration information describes that most standard tablets are intended to be swallowed whole to ensure the active ingredients are absorbed as designed. The official product information specifies that extended-release forms, if they exist, often have strict rules against altering their form. For patients who have trouble swallowing tablets, a liquid suspension formulation of the medicine is available.

Q: Is it necessary to finish the entire course of Plenobiotic Duo, even if feeling better?

A: Official patient information emphasizes that the medicine is prescribed to be taken exactly as directed for the full duration set by the healthcare professional. This means the complete course should be finished, even if symptoms begin to improve early. Regulatory guidance states that completing the full prescribed course is essential to ensure the intended outcome of the treatment.

Q: Are there restrictions on taking Plenobiotic Duo before surgery?

A: Regulatory guidelines and official literature indicate that this medicine is sometimes included in recommendations for surgical antimicrobial prophylaxis (pre-operative antibiotic use). The requirement and precise timing for antibiotic prophylaxis are detailed based on the procedure being performed.

Q: Is it common for Plenobiotic Duo to cause mild headaches?

A: Official safety information reports headache as a less frequently reported adverse reaction associated with this medicine. In clinical trials, the reported incidence of headache is often less than 1%. As with any unexpected changes, regulatory guidance suggests consulting a healthcare professional if this or any other adverse reaction is experienced.

Q: Does Plenobiotic Duo contain gluten, lactose, or common allergens?

A: Regulatory guidance requires that the presence of common inactive ingredients, known as excipients, such as gluten or lactose, must be specifically noted in the official data sheets for the product's particular formulation. This information is dependent on the specific manufacturing details for the tablets and suspensions.

Q: Are there common mental or mood-related changes associated with Plenobiotic Duo?

A: Regulatory documents list rare Central Nervous System (CNS) adverse reactions that may involve mood or mental status. These include reports of agitation, anxiety, behavioral changes, and confusion. Should such changes occur, regulatory guidance suggests consulting a healthcare professional.

Q: What are the official guidelines regarding alcohol consumption with Plenobiotic Duo?

A: Official information for the Amoxicillin component indicates that alcohol does not typically interfere with the drug's effectiveness. However, official guidance often notes that limiting or moderating alcohol intake is a standard part of recovery from any illness, and this principle generally applies while taking the medication.

Q: Can Plenobiotic Duo affect my sleep schedule?

A: Regulatory reports list insomnia (sleeplessness) as a potential adverse reaction related to Central Nervous System effects. Insomnia is generally among the less common side effects reported for this medication. If sleeplessness is severe or concerning, regulatory guidance suggests consulting a healthcare professional.

Q: What is the expected time frame for the drug to clear the system after stopping Plenobiotic Duo?

A: Regulatory pharmacokinetic data describes the clearance rate of the medicine's active components. The Amoxicillin component has an elimination half-life of approximately 1.3 hours in most individuals. Official data indicates this clearance time can be longer in individuals who are documented to have impaired kidney function.

Advertisements

How should Plenobiotic Duo be stored and disposed of?

Storage Requirements

Official labeling mandates different storage conditions based on the formulation. All forms of Plenobiotic Duo must be kept out of the sight and reach of children.

Dosage Form Temperature & Protection Stability Constraint
Tablets / Dry Powder Controlled room temperature (not above 25 C); Protect from moisture. Store in original, tightly closed container.
Reconstituted Suspension Must be refrigerated (2 C to 8 C); Do not freeze. Discard after 10 days of preparation.

Disposal Instructions

Unused or expired Plenobiotic Duo must be disposed of in accordance with local regulations for pharmaceutical waste. Regulatory documents state the product must not be thrown into household trash or disposed of via wastewater (sinks or toilets).

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Plenobiotic Duo found in:

A-Z Index: